Recurrent Pneumothorax after Etanercept Therapy in a Rheumatoid Arthritis Patient: A Case Report
10.4068/cmj.2014.50.3.115
- Author:
Sang Hoon KIM
1
;
Sung Jae CHOI
;
Young Ho SEO
;
Ji Hyoung KIM
;
Il Woo JEONG
;
Sung Birm SOHN
Author Information
1. Department of Internal Medicine, Korea University Medical Center, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Lung diseases, interstitial;
Pneumothorax;
Arthritis, rheumatoid
- MeSH:
Antirheumatic Agents;
Arthritis, Rheumatoid;
Humans;
Lung Diseases, Interstitial;
Necrosis;
Pneumothorax;
Adalimumab;
Etanercept
- From:Chonnam Medical Journal
2014;50(3):115-118
- CountryRepublic of Korea
- Language:English
-
Abstract:
The use of anti-tumor necrosis factor (anti-TNF) agents for rheumatoid arthritis (RA) patients who are refractory to disease-modifying anti-rheumatic drugs is gradually increasing. Etanercept is the first anti-TNF agent to be approved for RA treatment and is also the most widely used. However, aggravation of interstitial lung disease after etanercept treatment in RA patients has been reported recently. We report the first case of recurrent spontaneous pneumothorax with progression of interstitial lung disease after initiating etanercept therapy. The withdrawal of etanercept and a change to adalimumab, a different class of TNF inhibitor, achieved clinical stabilization.
